In this issue:
CD19.22.BBζ CAR T-cell therapy for those aged 3 to 39 years
Efficacy of PDPN-CAR T cell and GD2-CAR T cell blend
Functional T-cell responses after SARS-CoV-2 vaccination
Axi-cel versus tisa-cel for relapse/refractory follicular lymphoma
PET response for guiding post-CAR-T management
New toxicity management protocol for reducing CRS and ICANS
CD19-CAR T-cell therapy for children and young adults with EMD, iBM and CNS disease
Impact of age on CD19 CAR T-cell therapy efficacy
Prognostic impact of TP53 alterations
Long-term outcomes of CD19 CAR T-cell therapy
Please login below to download this issue (PDF)